Square Pharmaceuticals Limited reported unaudited consolidated earnings results for the second quarter and six months ended December 2016. For the quarter, the company reported consolidated EPS of BDT 3.58 for October-December, 2016 as against BDT 3.21 for October-December, 2015. For the six months, the company reported consolidated EPS of BDT 7.11 for July-December, 2016 as against BDT 6.10 for July-December, 2015. Consolidated NOCFPS was BDT 8.54 for July-December, 2016 as against BDT 8.93 for July-December, 2015. Consolidated NAV per share was BDT 63.00 as of December 31, 2016.